Julie Hambleton Biography and Net Worth

Dr. Julie Hambleton is a senior biotechnology executive with over 20 years of experience in clinical drug development. In addition to SpringWorks, Julie also serves as a member of the Board of Directors for Arch Oncology and IGM Biosciences. She served as interim President and Chief Executive Officer of Arch Oncology until 2021, and prior to that, Julie served as Senior Vice President, Chief Medical Officer and Head of Development at IDEAYA Biosciences until her retirement in 2020. Before IDEAYA, she was Vice President, Head of U.S. Medical at Bristol-Myers Squibb, overseeing Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios. Earlier, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics. Julie began her industry career at Genentech, most recently as Group Medical Director, Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin^®. Julie completed her medical and hematology-oncology training at the University of California, San Francisco, where she then served on faculty from 1993 to 2003. She received an M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine. She received her B.S. from Duke University.

What is Julie Hambleton's net worth?: The estimated net worth of Julie Hambleton is at least $71,180.00 as of July 25th, 2024. Dr. Hambleton owns 2,000 shares of SpringWorks Therapeutics stock worth more than $71,180 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Hambleton may own. Learn More about Julie Hambleton's net worth.
How do I contact Julie Hambleton?: The corporate mailing address for Dr. Hambleton and other SpringWorks Therapeutics executives is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. SpringWorks Therapeutics can also be reached via phone at 203-883-9490 and via email at [email protected]. Learn More on Julie Hambleton's contact information.
Has Julie Hambleton been buying or selling shares of SpringWorks Therapeutics?: Julie Hambleton has not been actively trading shares of SpringWorks Therapeutics in the last ninety days. Most recently, Julie Hambleton sold 2,418 shares of the business's stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $29.31, for a transaction totalling $70,871.58. Following the completion of the sale, the director now directly owns 4,648 shares of the company's stock, valued at $136,232.88. Learn More on Julie Hambleton's trading history.
Who are SpringWorks Therapeutics' active insiders?: SpringWorks Therapeutics' insider roster includes Badreddin Edris (COO), Julie Hambleton (Director), Saqib Islam (CEO), Daniel Pichl (Chief People Officer), L. Smith (Insider), and Stephen Squinto (Director). Learn More on SpringWorks Therapeutics' active insiders.
Are insiders buying or selling shares of SpringWorks Therapeutics?: In the last year, insiders at the sold shares 2 times. They sold a total of 35,000 shares worth more than $1,590,900.00. The most recent insider tranaction occured on December, 3rd when COO Badreddin Edris sold 20,000 shares worth more than $839,400.00. Insiders at SpringWorks Therapeutics own 7.6% of the company. Learn More about insider trades at SpringWorks Therapeutics.
Information on this page was last updated on 12/3/2024.

Julie Hambleton Insider Trading History at SpringWorks Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/19/2023	Sell	2,418	$29.31	$70,871.58	4,648
6/20/2023	Sell	2,400	$26.92	$64,608.00	7,066
3/15/2023	Sell	1,106	$31.50	$34,839.00	4,818

Julie Hambleton Buying and Selling Activity at SpringWorks Therapeutics

SpringWorks Therapeutics Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $35.59

$34.56

$35.94

50 Day Range

MA: $35.43

$28.61

$42.55

2 Week Range

Now: $35.59

$28.21

$53.92

Volume

1,260,985 shs

Average Volume

1,008,921 shs

Market Capitalization

$2.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.